GlassScriptPhysician profile
Mihaela Carter
NPI 1497027296
$6,238.13
in general payments reported to CMS, 2019-2025
15 companies · $838 in 2025
The $838 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $372 · 2020: $458 · 2021: $1,204 · 2022: $600 · 2023: $1,261 · 2024: $1,506 · 2025: $838.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,505 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,505.25 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $3,063.25 | 2019-2025 | Sunlenca, Veklury, Biktarvy |
| Viiv Healthcare Company | $1,169.34 | 2021-2025 | Cabenuva, Dovato, Apretude |
| Insmed, INC. | $405.27 | 2021-2025 | Arikayce |
| Merck Sharp & Dohme LLC | $262.11 | 2024-2025 | Pifeltro, Delstrigo, Zerbaxa |
| Abbvie INC. | $261.14 | 2021-2025 | Dalvance, Teflaro, Avycaz |
| Janssen Biotech, INC. | $252.17 | 2019-2021 | |
| Theratechnologies INC. | $222.26 | 2021-2025 | Egrifta, Trogarzo |
| Janssen Products, LP | $162.38 | 2021 | |
| Shionogi INC | $140.24 | 2022-2025 | Fetroja |
| Paratek Pharmaceuticals, INC. | $114.91 | 2023-2025 | Nuzyra |
| Melinta Therapeutics, LLC | $61.32 | 2023-2025 | Rezzayo, Kimyrsa, Vabomere |
| Aimmune Therapeutics, INC. | $40.86 | 2024-2025 | Vowst |
| Polymedics Innovations INC. | $36.06 | 2025 | |
| Ferring Pharmaceuticals INC. | $26.18 | 2024 | Rebyota |
| Napo Pharmaceuticals INC | $20.64 | 2023 | Mytesi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mihaela Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.